Skip to main content
Kent Academic Repository

Reactor-produced radioisotopes from ORNL for bone pain palliation

Knapp Jr., F.F.R., Mirzadeh, S., Beets, A.L., O'Doherty, Michael J., Blower, Philip J., Verdera, E.S., Gaudiano, J.S., Kropp, J., Guhlke, J., Palmedo, H., and others. (1996) Reactor-produced radioisotopes from ORNL for bone pain palliation. Applied Radiation and Isotropes, 49 (4). pp. 309-315. ISSN 0969-8043. (doi:10.1016/S0969-8043(97)00043-2) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:17402)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL:


The treatment of painful skeletal metastases is a common clinical problem, and the use of therapeutic radionuclides which localize at metastatic sites has been found to be an effective method for treatment of pain, especially for multiple sites for which the use of external beam irradiation is impractical. There are currently several metastatic-targeted agents radiolabeled with various therapeutic radionuclides which are in various stages of clinical investigation. Since neutron rich radionuclides are produced in research reactors and often decay by emission of beta(-) particles, most radionuclides used for bone pain palliation are reactor-produced. Key examples of radionuclides produced by single neutron capture of enriched targets include rhenium-186 and samarium-153. In addition, generator systems are also of interest which provide therapeutic daughter radionuclides from the decay of reactor-produced parent radionuclides. One important example is rhenium-188, available from generators via decay of reactor-produced tungsten-188. Tin-117m is an example of a reactor-produced radionuclide which decays with the emission of low-energy conversion electrons rather than by beta(-) decay. Each of these agents and/or radionuclides has specific advantages and disadvantages, however, the ideal agent for bone pain palliation has not yet been identified. The goal of this paper is to briefly review the production and use of several reactor-produced radionuclides for bone pain palliation, and to discuss the role of the ORNL High Flux Isotope Reactor(HFIR) for the production of many of these radionuclides.

Item Type: Article
DOI/Identification number: 10.1016/S0969-8043(97)00043-2
Additional information: Conference Information: Symposium on Measurements for Radionuclides Used for Bone Pain Palliation Therapy GAITHERSBURG, MARYLAND, SEP 17, 1996 Council Ionizing Rad Measurements & Stand, NIST Document Type: Proceedings Paper
Subjects: Q Science
Q Science > QD Chemistry
Divisions: Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research
Depositing User: M.A. Ziai
Date Deposited: 04 Apr 2009 18:37 UTC
Last Modified: 16 Nov 2021 09:55 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

Blower, Philip J..

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.